<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463889</url>
  </required_header>
  <id_info>
    <org_study_id>172016</org_study_id>
    <secondary_id>NCI-2018-00055</secondary_id>
    <nct_id>NCT03463889</nct_id>
  </id_info>
  <brief_title>Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer</brief_title>
  <official_title>Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen&#xD;
      positron emission tomography (PET) work in diagnosing patients with thyroid cancer.&#xD;
      Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and&#xD;
      find out how far the disease has spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility and utility of Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA) PET&#xD;
      imaging in patients with thyroid cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the correlation between targeted molecular uptake of 68Ga-PSMA PET in thyroid&#xD;
      cancer compared to areas identified as tumor by radioiodine uptake (in well-differentiated&#xD;
      cancers) or fludeoxyglucose F-18 (18F-FDG) uptake (in poorly differentiated and/or&#xD;
      radioiodine-negative cancers).&#xD;
&#xD;
      II. To determine and compare the sensitivity and specificity of 68Ga-PSMA PET to (18F-FDG)&#xD;
      PET and/or radioiodine scintigraphy.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if 68Ga-PSMA PET uptake is related to tumor differentiation and PSMA staining&#xD;
      in tissue pathology when available.&#xD;
&#xD;
      II. To determine the correlation between standardized uptake value maximum (SUVmax) of target&#xD;
      thyroid cancer lesions on 68Ga-PSMA PET and serum thyroglobulin levels.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive 68Ga-PSMA intravenously (IV) over 1-2 minutes and then undergo PET/MRI&#xD;
      60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion&#xD;
      of first scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of 68Ga PSMA-11 PET-positive Lesions</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The number of 68Ga PSMA-11 PET-positive lesions detected by staging scans will be descriptively reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Overall Detected Thyroid Cancer Lesions</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The number of overall thyroid cancer lesions detected by standard staging scans will be descriptively reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Standardized Uptake Value Maximum of Gallium-68 PSMA (SUVmax)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The mean and standard deviation for SUVmax across all lesions across all patients will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of Gallium-68 PSMA for the Detection of Thyroid Cancers</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true positive rate will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of Gallium-68 PSMA for the Detection of Thyroid Cancers</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Specificity is the agents ability to exclude the disease when the disease is absent. For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true negative rate will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Thyroid Gland Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</arm_group_label>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI in combination with PET</description>
    <arm_group_label>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging (NMRI)</other_name>
    <other_name>Nuclear Magnetic Resonance (NMR) Imaging</other_name>
    <other_name>NMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>Undergo PET in combination with MRI</description>
    <arm_group_label>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of thyroid cancer&#xD;
&#xD;
          -  Whole body 18F-FDG PET/computed tomography (CT) or I-131 scintigraphy within the past&#xD;
             90 days of the scheduled 68Ga-PSMA PET demonstrating uptake&#xD;
&#xD;
          -  Creatinine =&lt; 3.0 mg/dL&#xD;
&#xD;
          -  Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had active infection within 15 days of study enrollment that may be&#xD;
             considered to interfere with 68Ga-PSMA PET imaging by the study investigators&#xD;
&#xD;
          -  Patients who are unable to have placement of intravenous line access&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients not capable of undergoing a PET/MRI study due to weight, claustrophobia, or&#xD;
             inability to lie still for the duration of the exam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Flavell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <results_first_submitted>May 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Robert Flavell, MD, PhD</investigator_full_name>
    <investigator_title>Asst Professor in Residence</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03463889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
          <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
          <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years from initial diagnosis to study imaging</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of 68Ga PSMA-11 PET-positive Lesions</title>
        <description>The number of 68Ga PSMA-11 PET-positive lesions detected by staging scans will be descriptively reported.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
            <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of 68Ga PSMA-11 PET-positive Lesions</title>
          <description>The number of 68Ga PSMA-11 PET-positive lesions detected by staging scans will be descriptively reported.</description>
          <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
          <units>lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Overall Detected Thyroid Cancer Lesions</title>
        <description>The number of overall thyroid cancer lesions detected by standard staging scans will be descriptively reported</description>
        <time_frame>Up to 24 months</time_frame>
        <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
            <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Overall Detected Thyroid Cancer Lesions</title>
          <description>The number of overall thyroid cancer lesions detected by standard staging scans will be descriptively reported</description>
          <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
          <units>lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Standardized Uptake Value Maximum of Gallium-68 PSMA (SUVmax)</title>
        <description>The mean and standard deviation for SUVmax across all lesions across all patients will be reported.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
            <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standardized Uptake Value Maximum of Gallium-68 PSMA (SUVmax)</title>
          <description>The mean and standard deviation for SUVmax across all lesions across all patients will be reported.</description>
          <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity of Gallium-68 PSMA for the Detection of Thyroid Cancers</title>
        <description>For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true positive rate will be calculated.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
            <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of Gallium-68 PSMA for the Detection of Thyroid Cancers</title>
          <description>For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true positive rate will be calculated.</description>
          <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity of Gallium-68 PSMA for the Detection of Thyroid Cancers</title>
        <description>Specificity is the agents ability to exclude the disease when the disease is absent. For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true negative rate will be reported.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
            <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of Gallium-68 PSMA for the Detection of Thyroid Cancers</title>
          <description>Specificity is the agents ability to exclude the disease when the disease is absent. For each lesion detected on 18F-FDG PET or radioiodine scintigraphy (131I), the presence or absence of 68Ga-PSMA-11 uptake will be reviewed and tabulated. Presence on either 131I and 18F-FDG will be considered true positive disease. If additional lesions are detected on 68Ga-PSMA-11 as compared to 18F-FDG or 131I, the lesions will be characterized as either true or false positives in comparison to the appearance of the lesion on conventional imaging (thyroid ultrasound, CT and MRI). The gold standard for an individual lesion will be FDG or 131I, if the individual lesion is positive on either imaging study. If the lesions are not seen on either FDG or 131I, then consensus reading of conventional imaging will be performed to determine true and false positives lesions. Point estimate of the true negative rate will be reported.</description>
          <population>One patient with qualifying FDG PET/CT underwent surgical procedures prior to undergoing [68Ga]Ga-PSMA-11 PET/MRI and was therefore excluded from the analysis due to lack of comparability</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months</time_frame>
      <desc>Only grade 3 and higher adverse events were recorded</desc>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)</title>
          <description>Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.&#xD;
Gallium Ga 68-labeled PSMA-11: Given IV&#xD;
Magnetic Resonance Imaging: Undergo MRI in combination with PET&#xD;
Positron Emission Tomography (PET): Undergo PET in combination with MRI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed earlier than expected due to lack of funding. Due to the small sample size, comparative sub-group analyses could not be performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert Flavell, MD PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>877-827-3222</phone>
      <email>Robert.Flavell@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

